188,035 Shares in HilleVax, Inc. (NASDAQ:HLVX) Acquired by Verition Fund Management LLC

Verition Fund Management LLC purchased a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 188,035 shares of the company’s stock, valued at approximately $331,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Frazier Life Sciences Management L.P. increased its position in shares of HilleVax by 8.5% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company’s stock valued at $153,523,000 after acquiring an additional 835,590 shares during the period. Point72 Asset Management L.P. purchased a new stake in HilleVax during the 2nd quarter valued at about $6,960,000. Trium Capital LLP acquired a new position in shares of HilleVax in the third quarter valued at about $798,000. Affinity Asset Advisors LLC purchased a new position in shares of HilleVax in the second quarter worth about $3,844,000. Finally, Ensign Peak Advisors Inc lifted its holdings in shares of HilleVax by 164.8% during the second quarter. Ensign Peak Advisors Inc now owns 311,784 shares of the company’s stock worth $4,508,000 after purchasing an additional 194,038 shares during the period. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Trading Down 1.0 %

Shares of NASDAQ:HLVX opened at $1.96 on Friday. HilleVax, Inc. has a twelve month low of $1.55 and a twelve month high of $20.22. The company has a market cap of $97.63 million, a PE ratio of -0.63 and a beta of 0.81. The company’s 50 day moving average is $1.88 and its 200 day moving average is $4.20.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). Equities research analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.